Selection of cell donors using KIR and HLA for Patients with Acute Myelogenous Leukemia - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if the risk for relapse (return of a disease or condition) is lower among patients with KIR advantageous donors who receive a stem cell transplant. The results from this study can be used to help patients who receive stem cell transplants in the future.
What is the Condition Being Studied?
Patients with AML who receive a stem cell transplant

Who Can Participate in the Study?

Adults who:
- Have been diagnosed with acute myelogenous leukemia
- Are a candidate for stem cell transplant
- Have an unrelated donor for transplant (you may still consent to participate if you don't know the status of your donor)

Age Group

What is Involved?

This is an observational study
- There are no labs or study visits
- If you choose to participate, you will be asked to sign a consent form allowing Duke to send the study sponsor information from your medical record including survival, disease status, and treatment.

Study Details

Full Title
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00084344
NCT: NCT02450708
Phase N/A
Contact the Duke Recruitment Innovation Center